|Last Update: 05/24/13 - 4:00 PM EDT|
|YTD Performance: 48.15%|
|Previous Close: $85.60|
|52 Week Range: $30.06 - $95.85|
|Oustanding Shares: 72,783,040|
|Market Cap: 6,230,228,224|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||5||8||9||10|
|Growth Rate (Year over Year)||72.50%||-115.69%||-306.54%||-62.91%|
Shares of PCYC now seen reaching $90, accoridng to Credit Suisse. Estimates also increased, as Ibrutinib should drive growth. Outperform rating.
Shares of PCYC rated new Outperform, Credit Suisse said. $79 price target. Most derisked pure play in oral lymphoma/leukemia drug class.
PCYC was downgraded to Neutral, Lazard Capital Markets said. Company lacks near-term catalysts.
It's encouraging now to see the S&P hold onto most of those post fiscal cliff gains.
Adam Feuerstein, Sr. Columnist for TheStreet, says the American Society of Hematology meeting is the next big thing to watch in biotech.
My list doubles in size.
PCYC was downgraded from Buy to Hold, Needham said. Valuation call.
PCYC was initiated with a Market Perform rating, Bernstein said. $51 price target. Valuation call, as the stock is up 300% year-to-date. Also have below-consensus view of the company's key product.
These mid-caps are volatile, but a merger or major announcement could send them soaring.
The weak ISM number will eventually matter, but for now, traders are focused on technical conditions.